GitLab Inc
F:8K2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
GitLab Inc
F:8K2
|
US |
|
P
|
Puma SE
OTC:PUMSY
|
DE |
|
T
|
Teladoc Health Inc
F:4LL
|
US |
|
I
|
Innate Pharma SA
SWB:IDD
|
FR |
|
P
|
Primeenergy Resources Corp
F:PEJ
|
US |
|
BYD Co Ltd
LSE:0VSO
|
CN |
|
Gol Linhas Aereas Inteligentes SA
BMV:GOLN
|
BR |
|
C
|
Champion Pacific Indonesia Tbk PT
XMUN:IUD
|
ID |
|
E
|
Energizer Holdings Inc
SWB:EGG
|
US |
|
Innate Pharma SA
PAR:IPH
|
FR |
|
I
|
Innovative Industrial Properties Inc
F:1IK
|
US |
Wall St Price Targets
8K2 Price Targets Summary
GitLab Inc
According to Wall Street analysts, the average 1-year price target for
8K2 is 58.37 EUR with a low forecast of 42.75 EUR and a high forecast of 111.1 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 8K2's stock price target?
Price Target
58.37
EUR
According to Wall Street analysts, the average 1-year price target for
8K2 is 58.37 EUR with a low forecast of 42.75 EUR and a high forecast of 111.1 EUR.
What is the Revenue forecast for GitLab Inc?
Projected CAGR
14%
Over the last 5 years, the compound annual growth rate for Revenue has been 44%. The projected CAGR for the next 8 years is 14%.